Gilead to pay $11.9B for cancer treatment developer Kite

Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors

from ABC News: Health http://ift.tt/2whW5Et
via HEALTH